Cost and cost-effectiveness of treatments for rheumatic heart disease in low- and middle-income countries: a systematic review protocol.

IF 1.5 Q3 HEALTH CARE SCIENCES & SERVICES JBI evidence synthesis Pub Date : 2024-09-01 DOI:10.11124/JBIES-23-00246

Mona Thangamma Ag, Bhavya Vidyadharan, Roshan P Daniel, Andria Sirur, Praveen Kumar, Girish Thunga P, Pooja Gopal Poojari, Muhammed Rashid, Nirmalya Mukherjee, Paramita Bhattacharya, Denny John

{"title":"Cost and cost-effectiveness of treatments for rheumatic heart disease in low- and middle-income countries: a systematic review protocol.","authors":"Mona Thangamma Ag, Bhavya Vidyadharan, Roshan P Daniel, Andria Sirur, Praveen Kumar, Girish Thunga P, Pooja Gopal Poojari, Muhammed Rashid, Nirmalya Mukherjee, Paramita Bhattacharya, Denny John","doi":"10.11124/JBIES-23-00246","DOIUrl":null,"url":null,"abstract":"Objective: This review will synthesize studies on costs, the impact of these costs, and the cost-effectiveness of treatments for rheumatic heart disease (RHD) in low- and middle-income countries.Introduction: RHD incurs high costs owing to its clinical complexity, surgical treatments, and prolonged hospital stays. Thus, the disease has a substantial economic impact on the health system, patients, and their families. No systematic review on economic evidence of treatments for RHD has been published to date.Inclusion criteria: This review will consider all cost and cost-effectiveness studies on RHD treatments for children and young adults (5─30 years) residing in low- and middle-income countries.Methods: The review will follow the JBI methodology for systematic reviews of economic evaluation evidence. The search strategy will locate published and unpublished studies in English. Systematic searches will be conducted in MEDLINE (PubMed), MEDLINE (Ovid), Embase (Ovid), Scopus, CINAHL (EBSCOhost), National Health Service Economic Evaluation Databases, Pediatric Economic Database Evaluation, and Cost-Effectiveness Analysis Registry. Two independent reviewers will screen titles and abstracts, followed by a full-text review based on the inclusion criteria. Data will be extracted using a modified JBI data extraction form for economic evaluations. JBI's Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the results of cost and cost-effectiveness studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess the certainty of economic evidence for outcomes related to resource use.Review registration: PROSPERO CRD42023425850.","PeriodicalId":36399,"journal":{"name":"JBI evidence synthesis","volume":" ","pages":"1886-1897"},"PeriodicalIF":1.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JBI evidence synthesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11124/JBIES-23-00246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This review will synthesize studies on costs, the impact of these costs, and the cost-effectiveness of treatments for rheumatic heart disease (RHD) in low- and middle-income countries.

Introduction: RHD incurs high costs owing to its clinical complexity, surgical treatments, and prolonged hospital stays. Thus, the disease has a substantial economic impact on the health system, patients, and their families. No systematic review on economic evidence of treatments for RHD has been published to date.

Inclusion criteria: This review will consider all cost and cost-effectiveness studies on RHD treatments for children and young adults (5─30 years) residing in low- and middle-income countries.

Methods: The review will follow the JBI methodology for systematic reviews of economic evaluation evidence. The search strategy will locate published and unpublished studies in English. Systematic searches will be conducted in MEDLINE (PubMed), MEDLINE (Ovid), Embase (Ovid), Scopus, CINAHL (EBSCOhost), National Health Service Economic Evaluation Databases, Pediatric Economic Database Evaluation, and Cost-Effectiveness Analysis Registry. Two independent reviewers will screen titles and abstracts, followed by a full-text review based on the inclusion criteria. Data will be extracted using a modified JBI data extraction form for economic evaluations. JBI's Dominance Ranking Matrix for economic evaluations will be used to summarize and compare the results of cost and cost-effectiveness studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess the certainty of economic evidence for outcomes related to resource use.

Review registration: PROSPERO CRD42023425850.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中低收入国家治疗风湿性心脏病的成本和成本效益：系统性审查协议。

目的：本综述将综述有关中低收入国家风湿性心脏病（RHD）治疗成本、成本影响和成本效益的研究：本综述将综述有关中低收入国家治疗风湿性心脏病（RHD）的成本、这些成本的影响以及成本效益的研究：风湿性心脏病因其临床复杂性、手术治疗和长期住院而产生高昂的费用。因此，该疾病对医疗系统、患者及其家庭造成了巨大的经济影响。迄今为止，还没有发表过关于RHD治疗方法经济证据的系统性综述：本综述将考虑所有针对居住在中低收入国家的儿童和年轻成人（5-30 岁）的风疹治疗的成本和成本效益研究：方法：本综述将采用 JBI 方法对经济评估证据进行系统综述。检索策略将查找已发表和未发表的英文研究。将在 MEDLINE (PubMed)、MEDLINE (Ovid)、Embase (Ovid)、Scopus、CINAHL (EBSCOhost)、National Health Service Economic Evaluation Databases、Pediatric Economic Database Evaluation 和 Cost-Effectiveness Analysis Registry 中进行系统检索。两名独立审稿人将筛选标题和摘要，然后根据纳入标准进行全文审阅。将使用修改后的 JBI 经济评估数据提取表提取数据。将使用 JBI 的经济评估优势排序矩阵（Dominance Ranking Matrix）来总结和比较成本与成本效益研究的结果。推荐、评估、发展和评价分级法（GRADE）将用于评估与资源使用相关结果的经济证据的确定性：审查注册编号：PREMCOCRD42023425850。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊